drugset / Trial / NCT04557319

Safety and Pharmacokinetics of GNR-038 in Healthy Volunteers

NCT04557319

Phase 1 Completed 36 enrolled AO GENERIUM
Non-randomizedSequentialOpen-labelOther

Summary

It is an open-label dose-escalating study in sequential cohorts to assess safety and pharmacokinetics of GNR-038.

Timeline

Start
2020-03-10
Primary completion
2020-08-27
Completion
2020-08-27

Drugs

EvaluationDrugModalityDoseRoute
Subject GNR-038 Protein / enzyme biologic 25 iu/kg Intravenous
Subject GNR-038 Protein / enzyme biologic 50 iu/kg Intravenous
Subject GNR-038 Protein / enzyme biologic 100 iu/kg Intravenous

Indications